Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III-N2 Driver Gene-Negative Non-Small Cell Lung Cancer in the Immunotherapy Era - PubMed
4 days ago
- #Chemoradiotherapy
- #Non-Small Cell Lung Cancer
- #Immunotherapy
- Study compares three perioperative treatment strategies for Stage III-N2 driver gene-negative NSCLC in the immunotherapy era.
- Strategies include neoadjuvant chemoimmunotherapy followed by surgery (NCIT+Surgery), NCIT followed by chemoradiotherapy (NCIT+CRT), and definitive chemoradiotherapy followed by immunotherapy (CRT+IT).
- Primary endpoints were progression-free survival (PFS) and overall survival (OS).
- 363 patients were included, with median follow-up of 31.5 months.
- NCIT+Surgery showed longer PFS and OS compared to CRT+IT, but no significant difference was found between NCIT+Surgery and NCIT+CRT.
- Subgroup analysis revealed no significant survival difference between NCIT+Surgery and CRT+IT in patients with multistation or bulky N2 metastasis.
- CRT+IT was inferior in patients without multistation or bulky N2 features.
- Findings suggest CRT could be an alternative to surgery in certain patient subgroups, but requires validation in large-scale prospective studies.